12 results about "Mucosal Immune Responses" patented technology

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The invention provides a tulabacillus Tul4 protein trimer, according to the Tul4 protein trimer, an N-terminal natural Loop region of a monomer of the Tul4 protein trimer is used as flexible connection, Tul4 proteins are connected in series to form the trimer Tul4-trimer, the trimer can retain monomer conformation before fusion and fully expose important T cell epitopes of the monomer, an Ad5-Tul4-trimer vector based on type-5 adenovirus is constructed, and the tulabacillus Tul4 protein trimer can be used for preparing the Tul4 protein trimer. According to the present invention, the Tul4 trimer with the high expression can be obtained in the host cell, the Tul4 trimer can induce the efficient specific humoral immune response under the intramuscular injection and nasal drip immune pathway, the latter can induce the strong mucosal immune response, and the Tul4 trimer can be used for preparing the vaccine for preventing the Tul4 infection or the drug for treating the Tul4 infection.

The present application relates to the technical field of biological agents, and discloses a kind of M cell targeted peptide and chitosan modified dendritic mesoporous silica oral adjuvant and application thereof.The oral adjuvant includes dendritic mesoporous silica (DFNSs), and M cell targeted peptide (CKS9) modified chitosan (CS), the dendritic mesoporous silica is mixed with M cell targeted peptide modified chitosan at mass ratio 4-6:1, and is made into CKS9-CS-DFNSs oral nano adjuvant.The CKS9-CS-DFNSs oral nano adjuvant provided in the present application has good stability and safety, can effectively induce mucosal immune response and humoral immune response by oral immunization, improve the effect of oral vaccine immunization, and can be widely used in the preparation of animal inactivated vaccine, recombinant protein vaccine and polypeptide vaccine.The oral nano adjuvant preparation has low cost, simple process and is easy to mass-produce.

The invention belongs to the technical field of biology, relates to a haemophilus parasuis subunit vaccine as well as a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises a recombinant P3 protein and a recombinant P5 protein, the recombinant P3 protein is coded by a sequence shown in SEQ ID No.1, the recombinant P5 protein is coded by a sequence shown in SEQ ID No.2, and the recombinant P3 protein is coded by a sequence shown in SEQ ID No.2. The vaccine immunization can induce effective respiratory mucosa immune response, meanwhile, humoral immune and cellular immune response are remarkably induced, the safety is high, live pathogens are not involved in the vaccine preparation process, no adverse reaction is generated after immunization, and mucosa immunity can be activated when the vaccine immunizes a body; the required antigen content is obviously lower than that of the existing vaccine, the mucosal immunity is enhanced and the immune duration is prolonged by screening adjuvants, and a good immune protection effect can be provided.

The application discloses a recombinant lactococcus lactis oral vaccine, a preparation method and application thereof, characterized in that the recombinant lactococcus lactis expresses TcCTL-2 and / or TcCTL-5. The oral vaccine can not only effectively induce a mouse to produce a high-efficiency intestinal mucosal immune response, but also can stimulate the body to produce cellular immunity. The recombinant lactococcus lactis expressing TcCTL-2 and TcCTL-5 has the best protection effect on the mouse, and can be used as a preferred oral vaccine strain for preventing canine toxocariasis.

The invention belongs to the technical field of biological vaccines. The invention particularly relates to a recombinant bacteriophage capable of inducing mucosal immune response and application of the recombinant bacteriophage. Specifically, a pVIII capsid protein is utilized to display a SpyCatcher protein on the surface of an M13 bacteriophage particle (for example, through a pVIII-trimer parallel coiled spiral structure coiled-coil-SpyCatcher structure), and an antigen protein is coupled through SpyCatcher and SpyTag, so that the antigen protein is efficiently displayed on the surface of the bacteriophage, and the recombinant M13 bacteriophage is obtained. The capsid protein of the recombinant M13 bacteriophage can display hundreds of copies of same epitopes, the natural structure on the surface of a pathogen is simulated by the highly dense and highly repeated antigen arrangement mode, a B cell receptor is effectively cross-linked, a strong humoral immune response is induced, and no extra adjuvant is needed.

The present disclosure provides a novel method for modulating mucosal immune response, comprising administering an antigen to a mucosal site of a subject in need thereof, and administering an immunomodulator to a different anatomical mucosal site of said subject. The antigen may be administered to sublingual mucosa and the immunomodulator may be administered to intranasal mucosa. An immune response involving production of IgG and IgA against the antigen may be elicited.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.

The application belongs to the technical field of biological pharmacy, and discloses a recombinant lactococcus lactis live carrier vaccine, which is obtained by connecting a urease subunit UreA gene with a plasmid expression vector and then electrically transforming the lactococcus lactis; the amino acid sequence of the urease subunit UreA gene is shown as SEQ ID NO. 1. The application further discloses application of the recombinant lactococcus lactis live carrier vaccine in preparation of an anti-helicobacter pylori vaccine. The recombinant lactococcus lactis live carrier vaccine provided by the application can effectively stimulate the body to produce a mucosal immune response and has good protection effect.

The application discloses a preparation method of a PEDV COE subunit vaccine targeting M cells and application thereof. The application connects RGD peptide targeting M cells, a core neutralizing epitope COE region on a PEDV S protein and a fluorescent protein, expresses a recombinant protein, introduces a sulfur-containing amino acid into the protein to facilitate modification of the recombinant protein and connection of the protein to other substances in a covalent bond mode, and obtains a safe and effective mucosal subunit vaccine with green fluorescent labeling. Unlike common vaccines, the antigen of the vaccine can not only be directly taken by dendritic cells, but also be presented to dendritic cells through targeting M cells, the antigen presentation efficiency is significantly improved, the downstream immunity is more effectively started, and a series of immune responses of the body are induced, so that the mucosal immune system of the body produces a large number of PEDV specific antibodies to resist invasion of external pathogens, and the effect of specific immune protection is achieved.

The application provides a virus in the preparation of bacteriophage, and belongs to the technical field of bacteriophage. The application provides PCV2, phPCV2, PCV3, phPCV3, HEV or phHEV in the preparation of bacteriophage. The application first proposes that eukaryotic viruses can infect bacteria and can replicate in the bacteria, and the viruses show the characteristics of lysogenic bacteriophage. The application has broad spectrum for the infection of the bacteria, can effectively inhibit the reproduction of the bacteria, and has a pioneering significance for developing broad-spectrum bacteriophage bactericides and developing vaccines by using the infection of the viruses on the bacteria. The application can stably amplify the viruses with high toxicity by using Escherichia coli, and the inactivated vaccines prepared by the viruses can significantly protect animals. The application also prepares a RecA-deficient Bacillus subtilis live vector vaccine, so that the virus infection is stably in a lysogenic state for a long time, and the animals are inoculated by oral administration, the animals are colonized in the intestinal tract, and the antigen is continuously expressed to induce a mucosal immune response.